Search

To the best of our knowledge, no study has systematically reviewed and analyzed the research trends of wild-simulated ginseng (WSG) used for food or medicinal purposes in many countries. WSG, a non-timber forest product, has been traditionally produced using agroforestry practices, and it has been consumed in various ways for a long time. WSG has a great demand in the market due to its medicinal effects, particularly in improving forest livelihoods and human health. Due to the significance of WSG, we conducted this research to explore the global research trends on WSG using systematic review methodology and keyword analysis. We used two international academic databases, the Web of Science and SCOPUS, to extract 115 peer-reviewed articles published from 1982 to 2020. The research subjects, target countries, and keywords were analyzed. Our results indicate four categories of WSG research subjects, namely growth conditions, components, effects on humans/animals, and the environment of WSG, and the case studies were mainly from the Republic of Korea, China, and the USA. Through topic modelling, research keywords were classified into five groups, namely medicinal effects, metabolite analysis, genetic diversity, cultivation conditions, and bioactive compounds. We observed that the research focus on WSG changed from the biological properties and cultivation conditions of WSG to the precise identification and characterization of bioactive metabolites of WSG. This change indicates an increased academic interest in the value-added utilization of WSG. [ABSTRACT FROM AUTHOR]

Abstract: The fruit of Schizandra chinensis Baillon is a well-known traditional medicinal plant in Korea, China and Japan. We examined the effects of gamma irradiation on decolourisation and biological activity of S. chinensis fruit extracts to facilitate industrial applications. Samples were exposed to gamma-ray irradiation from 0.5 to 10kGy. Irradiation of greater than 2kGy markedly reduced the major colourant in S. chinensis fruit extracts, cyanidin-3-O-xylosylrutinoside (Cya-3-O-xylrut), by 80–90%. Biological activities, such as radical-scavenging activity and elastase inhibition activity, were not affected by gamma irradiation, but we observed a 12.3% increase in tyrosinase inhibition activity. There were negligible changes in the amounts of the major lignans schizandrin, gomisin A and gomisin N, following irradiation. These results indicated that gamma irradiation can selectively remove undesirable colour in S. chinensis extracts without adverse changes in biological activity. [ABSTRACT FROM AUTHOR]

Background: Resting heart rate (RHR) is considered as a strong predictor of total mortality and hospitalization due to heart failure in hypertension patients. Bisoprolol fumarate, a second-generation beta-adrenoreceptor blockers (β-blocker) is commonly prescribed drug to manage hypertension. The present study was to retrospectively evaluate changes in the average RHR and its association with cardiovascular outcomes in bisoprolol-treated coronary artery disease (CAD) patients from the CAD treated with bisoprolol (BISO-CAD) study who had comorbid hypertension., Methods: We performed ad-hoc analysis for hypertension sub-group of the BISO-CAD study (n = 866), which was a phase IV, multination, multi-center, single-arm, observational study carried out from October 2011 to July 2015 across China, South Korea, and Vietnam. Multivariate regression analysis was used to identify factors associated with incidence of composite cardiac clinical outcome (CCCO), the results were presented as adjusted odds ratio (OR) along with 95% confidence interval (CI) and adjusted P value., Results: A total of 681 patients (mean age: 64.77 ± 10.33 years) with hypertension from BISO-CAD study were included in the analysis. Bisoprolol improved CCCOs in CAD patients with comorbid hypertension, with RHR <65 and <70 beats/min compared with RHR ≥65 and ≥75 beats/min, respectively, in the efficacy analysis (EA) set. In addition, it lowered RHR in both intent-to-treat (ITT) and EA groups after 6, 12, and 18 months of treatment. Further, RHR 70 to 74 beats/min resulted in significantly higher risk of CCCOs EA set of patients (adjusted OR: 4.34; 95% CI: 1.19-15.89; P = 0.03). Also, events of hospitalization due to acute coronary syndrome were higher when RHR 69 to 74 beats/min compared to RHR <69 beats/min in ITT patients., Conclusion: Bisoprolol can effectively reduce RHR in Asian CAD patients with comorbid hypertension and hence, improve CCCO without affecting their blood pressure.

Objective: To evaluate the association between decrease in resting heart rate (RHR) and occurrence of composite cardiac clinical outcomes in coronary artery disease (CAD) patients after bisoprolol treatment., Methods: This phase IV, multi-national, single-arm, open-label, non-randomized, observational trial was conducted between October 2011 and July 2015 across 42 hospitals from China, South Korea and Vietnam., Results: Analysis of 866 patients (mean age 63.85 ± 10.35; mean RHR at baseline 75.71 ± 6.87 bpm in intent-to-treat [ITT]; 75.56 ± 6.73 in efficacy analysis [EA] sets) was performed. Patients with lower mean RHR had fewer composite cardiac events and patients with RHR of 69-74 bpm reported significantly higher outcomes than patients with RHR <65 bpm (p = .0449). A significant association with occurrence of the composite cardiac outcome and hospital admission for unstable angina or revascularization was reported in the EA set (regression estimate: 0.03, 95% CI 0.00-0.07, p = .0412) and not in the ITT set for bisoprolol treated CAD patients. Composite cardiac outcomes significantly increased in patients with mean RHR ≥70 bpm compared to patients with mean RHR <70 bpm (p = .0328). Adverse events (AEs) were reported in 206 (23.8%) patients, of whom 102 (11.8%) patients had serious adverse event (SAEs). Among the patients with SAEs, 11 (1.3%) patients died. Treatment related adverse events were only 12 (1.4%). No treatment related SAE happened., Conclusion: The findings showed bisoprolol to be efficacious, in terms of lowering RHR and causing a significant decrease in the occurrence of the composite cardiac outcome, as well as safe in Asian patients with CAD.